1 / 13

The Innovation Agenda (A discussion not a lecture!)

The Innovation Agenda (A discussion not a lecture!). Prof. Brook K. Baker UKZN IPRs and Access to Medicines 2010. Problems with the Current Patent Regime. Emphasis on blockbuster drugs – chronic diseases affecting rich people.

olympe
Télécharger la présentation

The Innovation Agenda (A discussion not a lecture!)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The Innovation Agenda(A discussion not a lecture!) Prof. Brook K. Baker UKZN IPRs and Access to Medicines 2010

  2. Problems with the Current Patent Regime • Emphasis on blockbuster drugs – chronic diseases affecting rich people. • Wasted R&D (evergreening, me-too, marketing studies, disease mongering). • Neglected diseases neglected.

  3. Additional Problems – Innovation Gridlock • Upstream patent blocks, e.g., research method patents, platform patents • Patent thicket • Identifying and combining multiple, complex patents • Transaction costs • Royalty holdouts

  4. Additional Problems • Research silos and secrecy. • Winner takes all.

  5. Biggest Problem • Results in monopoly pricing which typically favors rich people and excludes poor people especially in high income-unequal countries. • Stronger patents, longer patents, more patents, and more enforcement just compound the problem.

  6. What are the alternatives? • If the patent regime is inefficient and inequitable, what are the solutions? • What other methods are there for promoting innovative medicines • In particular how do we promote research that is therapeutically significant for Africans? • Break into groups of 3 and brainstorm?

  7. Debrief • Report back from your group. • Try to create categories

  8. Open Source/Collaborative Solutions • We might get better and more R&D if researchers collaborate with each other and share both successes and failures. • Building on successes • Not duplicating failures • Examples: sharing chemical libraries, research outcomes, joint work • Special efforts to involve African researchers

  9. “Push” Mechanisms • More research grants from governments and charities • Public/private partnerships • Do you support basic research? • Do you focus on translational (final product) research)? • Do you try to target particular medical problems? • Can government bureaucrats choose wisely/non-corruptly?

  10. “Pull” Mechanisms • Advance Market Commitments or purchasing funds • Medical Innovation Fund • Prize Funds • Patent buy-outs • Enhanced tax incentives • Wild-card patent extensions • Extended orphan/neglected disease drug market exclusivity

  11. Battlegrounds for Innovation Policy • WHO Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property • Proposed R&D Treaty • WIPO Development Agenda • Is this important for Africa? For African activists?

  12. An African Research Agenda • Read the Bamako Call to Action on Research for Health, pp. 228-231.

  13. An African Research Agenda • What should be done to build research and development capacity in Africa? • Should African researchers focus on neglected African diseases? • What kind of incentives should there be for African researchers? • Should African researchers focus significantly on traditional medicines?

More Related